RESEARCH ALLIANCE CORPORATION III ANNOUNCES PRICING OF $75 MILLION INITIAL PUBLIC OFFERING

Research Alliance Corporation III has announced the pricing of its initial public offering (IPO) of 7,500,000 Class A ordinary shares at a price of $10.00 per share, aiming to raise a total of $75 million. The shares are set to be listed on the Nasdaq Capital Market under the ticker symbol "RACC," with trading commencing on May 20, 2026. The offering is expected to close on May 21, 2026, subject to customary closing conditions.

Research Alliance Corporation III is a special purpose acquisition company (SPAC) sponsored by an affiliate of RA Capital Management, L.P. The company is led by CEO Matthew Hammond, PhD, MBA, and CBO/COO Henry Stusnick. As a blank check company, Research Alliance is designed to effect a merger, share exchange, asset acquisition, or similar business combination with one or more businesses or entities. While the company has the flexibility to pursue opportunities across various sectors, it has indicated a strategic focus on the healthcare industry, leveraging the expertise of its management team to identify and acquire promising targets.

The healthcare sector remains a dynamic and attractive space for investment, particularly in light of ongoing innovations and the increasing demand for healthcare solutions. SPACs have gained popularity as a vehicle for companies seeking to enter public markets, offering a streamlined alternative to traditional IPOs. Research Alliance's focus on healthcare aligns with broader market trends, where investors are increasingly looking for opportunities that capitalize on advancements in biotechnology, pharmaceuticals, and healthcare services.

The participation of notable institutional investors, including ADAR1 Capital, Affinity Asset Advisors, and Balyasny Asset Management, among others, underscores the confidence in Research Alliance's potential to identify and execute successful acquisitions. This backing not only provides financial resources but also adds credibility to the company as it embarks on its journey in the public markets.

As the IPO landscape continues to evolve, the successful launch of Research Alliance Corporation III could signal renewed interest in SPACs, particularly those targeting the healthcare sector. The anticipated closing of this offering may pave the way for further SPAC transactions, as investors seek to capitalize on the growth opportunities presented by innovative healthcare companies. The market will be closely watching how Research Alliance leverages its capital and expertise to identify and execute a successful business combination in the coming months.